Avenda Health Raises $10M in Series B, Innovating Detection and Treatment for Prostate Cancer Care
Summary
CULVER CITY, Calif., Aug. 25, 2022 /PRNewswire/ -- , an AI healthcare company creating the future of personalized prostate cancer care, today announced it has raised $10M in Series B funding led by VCapital. At the 2022 American Urological Association annual meeting, a retrospective study of 50 patients showed iQuest improved tumor encapsulation1 over conventional treatment planning from 56 percent to 80 percent2. "We are thrilled to be a part of Avenda Healths journey in making incredible strides in the future of prostate cancer care, said Ryan Kole, Partner at VCapital. Priester A, Fan R, Shubert J, Colina J, Rusu M, Sulaiman V, Shao W, Khandiwala YS, Natarajan S, Sonn GA., A novel AI-derived metric identifies favorable candidates for focal therapy of prostate cancer and accurately predicts treatment margin efficacy. Priester A, Fan R, Shubert J, Colina J, Rusu M, Sulaiman V, Shao W, Khandiwala YS, Natarajan S, Sonn GA., Defining prostate cancer focal therapy treatment margins with a machine learning model: improvement upon hemi-gland ablation.